TY - JOUR T1 - Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients JF - Archives of Disease in Childhood JO - Arch Dis Child SP - 969 LP - 973 DO - 10.1136/adc.88.11.969 VL - 88 IS - 11 AU - B R Allen AU - M Lakhanpaul AU - A Morris AU - S Lateo AU - T Davies AU - G Scott AU - M Cardno AU - M-E Ebelin AU - P Burtin AU - T J Stephenson Y1 - 2003/11/01 UR - http://adc.bmj.com/content/88/11/969.abstract N2 - Aims: To measure pimecrolimus blood concentrations and to evaluate tolerability and efficacy in children and infants treated topically for atopic dermatitis with pimecrolimus cream 1% for three weeks. Methods: Three open label, non-controlled, multiple topical dose studies were conducted in children aged 8–14 years (study A, ten patients), and in infants aged 8–30 months (study B, eight patients) and 4–11 months (study C, eight patients). Pimecrolimus blood concentrations were determined on days 4 and 22 of treatment, and at end of study. Efficacy was assessed using the Eczema Area and Severity Index (EASI). Results: Pimecrolimus blood concentrations were consistently low, typically (81%) below 1 ng/ml, with more than half of the measurements below the assay limit of quantitation (0.5 ng/ml) in studies A and B. The highest blood concentration measured throughout the three studies was 2.6 ng/ml. The cream was well tolerated, locally and systemically. The most common adverse event suspected to be related to study medication was a transient mild to moderate stinging sensation at the application site in 5/26 patients. There was no indication of any systemic adverse effect. The patients responded well to therapy with a rapid onset of action, usually within four days. Median reductions of EASI from baseline at day 22 were 55% (study A), 63% (study B), and 83% (study C). Conclusion: Three weeks treatment of children and infants with extensive atopic dermatitis, using pimecrolimus cream 1% twice daily, is well tolerated and results in minimal systemic exposure, at which no systemic effect is expected. ER -